drugset / Trial / NCT06806826

The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study

NCT06806826

Phase 4 Completed 50 enrolled Yuzuncu Yil University
RandomizedParallel-groupOpen-labelTreatment

Summary

We aimed to evaluate the usability and efficacy of omalizumab in allergic rhinitis and its potential as an alternative treatment option.

Timeline

Start
2019-01-01
Primary completion
2020-01-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody 300 mg Subcutaneous

Indications